Eileen E. Parkes

2.2k total citations · 1 hit paper
36 papers, 1.0k citations indexed

About

Eileen E. Parkes is a scholar working on Oncology, Immunology and Molecular Biology. According to data from OpenAlex, Eileen E. Parkes has authored 36 papers receiving a total of 1.0k indexed citations (citations by other indexed papers that have themselves been cited), including 25 papers in Oncology, 16 papers in Immunology and 7 papers in Molecular Biology. Recurrent topics in Eileen E. Parkes's work include Cancer Immunotherapy and Biomarkers (16 papers), interferon and immune responses (12 papers) and Cancer Research and Treatments (6 papers). Eileen E. Parkes is often cited by papers focused on Cancer Immunotherapy and Biomarkers (16 papers), interferon and immune responses (12 papers) and Cancer Research and Treatments (6 papers). Eileen E. Parkes collaborates with scholars based in United Kingdom, United States and Spain. Eileen E. Parkes's co-authors include Richard D. Kennedy, Weiyi Peng, Hussein A. Tawbi, Justin T. Moyers, Timothy A. Yap, Michael A. Curran, Laura E. Taggart, Stephen McQuaid, Nuala McCabe and Niamh E. Buckley and has published in prestigious journals such as Journal of Clinical Oncology, JNCI Journal of the National Cancer Institute and Cancer Research.

In The Last Decade

Eileen E. Parkes

33 papers receiving 1.0k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Development of Immunotherapy Combination Strategies in Cancer

2021 231 citations Eileen E. Parkes et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Eileen E. Parkes United Kingdom	12	541	441	435	157	149	36	1.0k
Anita K. Mehta United States	12	457 0.8×	442 1.0×	345 0.8×	118 0.8×	162 1.1×	20	970
Jingwei Sun China	11	717 1.3×	438 1.0×	753 1.7×	193 1.2×	109 0.7×	22	1.3k
Casey R. Ager United States	12	507 0.9×	399 0.9×	685 1.6×	162 1.0×	247 1.7×	27	1.1k
Minlin Jiang China	12	410 0.8×	574 1.3×	453 1.0×	288 1.8×	246 1.7×	29	1.2k
Maria Libera Ascierto United States	19	677 1.3×	397 0.9×	577 1.3×	188 1.2×	181 1.2×	44	1.2k
Lerong Li United States	14	827 1.5×	699 1.6×	386 0.9×	215 1.4×	175 1.2×	21	1.4k
James M. Leatherman United States	13	461 0.9×	271 0.6×	443 1.0×	84 0.5×	93 0.6×	26	814
James Monkman Australia	15	357 0.7×	301 0.7×	208 0.5×	108 0.7×	180 1.2×	41	770
Allison R. Greenplate United States	19	465 0.9×	526 1.2×	681 1.6×	80 0.5×	178 1.2×	31	1.3k
Trevor Clancy Norway	18	326 0.6×	439 1.0×	358 0.8×	95 0.6×	112 0.8×	37	891

Countries citing papers authored by Eileen E. Parkes

Since Specialization

Citations

This map shows the geographic impact of Eileen E. Parkes's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Eileen E. Parkes with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Eileen E. Parkes more than expected).

Fields of papers citing papers by Eileen E. Parkes

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Eileen E. Parkes. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Eileen E. Parkes. The network helps show where Eileen E. Parkes may publish in the future.

Co-authorship network of co-authors of Eileen E. Parkes

This figure shows the co-authorship network connecting the top 25 collaborators of Eileen E. Parkes. A scholar is included among the top collaborators of Eileen E. Parkes based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Eileen E. Parkes. Eileen E. Parkes is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Grippin, Adam, DaeYong Lee, Eileen E. Parkes, Wen Jiang, & Betty Y.S. Kim. (2025). Nanotechnology for immuno-oncology. Nature Cancer. 6(8). 1311–1325. 3 indexed citations

Barberis, Alessandro, Clemens Lang, Guillaume Rieunier, et al.. (2025). IGF-1 regulates cancer cell immune evasion in prostate cancer. Scientific Reports. 15(1). 38422–38422.

Harrington, Kevin J., Shigehisa Kitano, Valentina Gambardella, et al.. (2025). Open-label, phase Ia study of STING agonist BI 1703880 plus ezabenlimab for patients with advanced solid tumors. Future Oncology. 21(2). 195–200. 2 indexed citations

Jackson, Ashley, Pradeep S. Virdee, Sharon Tonner, et al.. (2024). Validity and timeliness of cancer diagnosis data collected during a prospective cohort study and reported by the English and Welsh cancer registries: a retrospective, comparative analysis. The Lancet Oncology. 25(11). 1476–1486. 3 indexed citations

Parkes, Eileen E., et al.. (2023). Targeting mitotic regulators in cancer as a strategy to enhance immune recognition. DNA repair. 132. 103583–103583.

Lau, Doreen, Samuel L. Hill, D. Boulanger, et al.. (2023). Reactivation of low avidity tumor-specific CD8⁺ T cells associates with immunotherapeutic efficacy of anti-PD-1. Journal for ImmunoTherapy of Cancer. 11(8). e007114–e007114. 8 indexed citations

Vugt, Marcel A.T.M. van & Eileen E. Parkes. (2022). When breaks get hot: inflammatory signaling in BRCA1/2-mutant cancers. Trends in cancer. 8(3). 174–189. 35 indexed citations

Kopetz, Scott, Van K. Morris, Bert H. O’Neil, et al.. (2022). A multi-arm, phase 2, open-label study to assess the efficacy of RXC004 as monotherapy and in combination with nivolumab in patients with ring finger protein 43 (RNF43) or R-spondin (RSPO) aberrated, metastatic, microsatellite stable colorectal cancer following standard treatments.. Journal of Clinical Oncology. 40(16_suppl). TPS3637–TPS3637. 6 indexed citations

Parkes, Eileen E., Elaine S. Gilmore, Victoria Bingham, et al.. (2021). The clinical and molecular significance associated with STING signaling in breast cancer. npj Breast Cancer. 7(1). 81–81. 27 indexed citations

10.

Philippou, Yiannis, Hanna Sjoberg, Emma Murphy, et al.. (2020). Impacts of combining anti-PD-L1 immunotherapy and radiotherapy on the tumour immune microenvironment in a murine prostate cancer model. British Journal of Cancer. 123(7). 1089–1100. 49 indexed citations

11.

Willenbrock, Frances, Catrin Cox, Eileen E. Parkes, et al.. (2020). Circulating biomarkers and outcomes from a randomised phase 2 trial of gemcitabine versus capecitabine-based chemoradiotherapy for pancreatic cancer. British Journal of Cancer. 124(3). 581–586. 10 indexed citations

12.

McManus, Damian, Stephen McQuaid, Jacqueline A. James, et al.. (2019). Alcohol intake, tobacco smoking, and esophageal adenocarcinoma survival: a molecular pathology epidemiology cohort study. Cancer Causes & Control. 31(1). 1–11. 19 indexed citations

13.

Gilmore, Elaine S., Nuala McCabe, Richard D. Kennedy, & Eileen E. Parkes. (2019). DNA Repair Deficiency in Breast Cancer: Opportunities for Immunotherapy. Journal of Oncology. 2019. 1–14. 26 indexed citations

14.

Humphries, Matthew P., Seán O. Hynes, Victoria Bingham, et al.. (2018). Automated Tumour Recognition and Digital Pathology Scoring Unravels New Role for PD-L1 in Predicting Good Outcome in ER-/HER2+ Breast Cancer. Journal of Oncology. 2018. 1–14. 45 indexed citations

15.

Lightbody, Gaye, Valeriia Haberland, Fiona Browne, et al.. (2018). Review of applications of high-throughput sequencing in personalized medicine: barriers and facilitators of future progress in research and clinical application. Briefings in Bioinformatics. 20(5). 1795–1811. 108 indexed citations

16.

Parkes, Eileen E., Jaine K. Blayney, Éamon P McCarron, et al.. (2017). PD-L1 expression and response to neo-adjuvant chemotherapy in esophageal adenocarcinoma.. Journal of Clinical Oncology. 35(15_suppl). 4023–4023. 1 indexed citations

17.

Parkes, Eileen E., Steven M. Walker, Laura E. Taggart, et al.. (2016). Activation of STING-Dependent Innate Immune Signaling By S-Phase-Specific DNA Damage in Breast Cancer. JNCI Journal of the National Cancer Institute. 109(1). djw199–djw199. 341 indexed citations

18.

Parkes, Eileen E. & Richard D. Kennedy. (2016). Clinical Application of Poly(ADP-Ribose) Polymerase Inhibitors in High-Grade Serous Ovarian Cancer. The Oncologist. 21(5). 586–593. 24 indexed citations

19.

Walker, Steven M., Nuala McCabe, Eileen E. Parkes, et al.. (2016). An innate immune response to intrinsic DNA damage predicts resistance to docetaxel in prostate cancer. Annals of Oncology. 27. vi256–vi256. 1 indexed citations

20.

Buckley, Niamh E., Ricardo De Matos Simoes, Eileen E. Parkes, et al.. (2016). A BRCA1 deficient, NFκB driven immune signal predicts good outcome in triple negative breast cancer. Oncotarget. 7(15). 19884–19896. 25 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact